In The News: June 2013

Oral tofacitinib (Xeljanz) has been shown to inhibit structural progression and joint damage in patients with rheumatoid arthritis (RA), according to an international phase III trial published in Arthritis & Rheumatism (March 2013). The 12-month analysis examined the effects of two years of treatment on joint preservation, RA disease activity and physical function in 797 patients with active disease, and at least three joint erosions or serologic evidence of rheumatoid factor or antibodies to cyclic citrullinated peptide.
To continue reading this article or issue you must be a paid subscriber. Sign in

Subscribe to Arthritis Advisor

Get the next year of Arthritis Advisor for just $20. And access all of our online content - over 1,000 articles - free of charge.
Subscribe today and save 36%. It's like getting 4 months FREE!
Already Subscribed?
Click Here to Sign In | Forgot your password? | Activate Web Access